Skip to main content

Advertisement

SpringerLink
Log in

Opioid Use Disorders in Adolescents—Updates in Assessment and Management

  • Adolescent Medicine (M Goldstein and L Johnson, Section Editors)
  • Published:
Current Pediatrics Reports Aims and scope Submit manuscript

Abstract

Purpose of Review

To review information specific to adolescents regarding trends in opioid use, risk factors for opioid misuse, medical co-morbidity, and treatment updates.

Recent Findings

Although opioid misuse in adolescents is uncommon, it is associated with morbidity and mortality such as hepatitis C and overdose. Adolescents commonly start with prescription opioid misuse before transitioning to heroin use. The existing literature supports the use of buprenorphine/naloxone for the treatment of adolescent opioid use disorders. Safe medication storage and disposal is important to decrease adolescent prescription opioid misuse.

Summary

Opioid misuse occurs in adolescents, and pediatric providers need to remain up to date.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. Control CfD. Total U.S. drug deaths. National Institute on Drug Abuse Advancing Addiction Science: CDC WONDER; 2017. p. More than 64,000 Americans died from drug overdoses in 2016, including illicit drugs and prescription opioids—nearly double in a decade.

  2. Center for Disease Control. Vital signs: overdoses of prescription opioid pain relievers—United States, 1999-2008. MMWR Surveill Summ. 2011;60:1–6.

    Google Scholar 

  3. • Rudd RA, Aleshire N, Zibbell JE, Gladden RM. Increases in drug and opioid overdose deaths—United States, 2000–2014. MMWR Morb Mortal Wkly Rep. 2016;64(50–51):1378–82. Provides information on the number of drug overdose deaths in 2015 with details on regional changes and the type of synthetic opioids involved.

  4. •• Curtin SC, Tejada-Vera B, Warmer M. Drug overdose deaths among adolescents aged 15–19 in the United States: 1999–2015. NCHS Data Brief. 2017;(282):1–8. Provides information on trends in drug overdose deaths in adolescents including details on gender, intentionality of overdose, and substances involved in the overdose.

  5. Compton WM, Thomas YF, Stinson FS, Grant BF. Prevalence, correlates, disability, and comorbidity of DSM-IV drug abuse and dependence in the United States: results from the national epidemiologic survey on alcohol and related conditions. Arch Gen Psychiatry. 2007;64(5):566–76.

    Article  PubMed  Google Scholar 

  6. 2016 National Survey on Drug Use and Health: detailed tables. Rockville, MD Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality; 2017.

  7. Martins SS, Segura LE, Santaella-Tenorio J, Perlmutter A, Fenton MC, Cerda M, et al. Prescription opioid use disorder and heroin use among 12-34 year-olds in the United States from 2002 to 2014. Addict Behav. 2017;65:236–41.

    Article  PubMed  Google Scholar 

  8. Mental Health Annual Report: 2015. Use of mental health services: national client level data. Rockville, MD: Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality.; 2015.

  9. McCabe SE, West BT, Veliz P, McCabe VV, Stoddard SA, Boyd CJ. Trends in medical and nonmedical use of prescription opioids among US adolescents: 1976–2015. Pediatrics. 2017;139(4).

  10. McCabe SE, Veliz P, Schulenberg JE. Adolescent context of exposure to prescription opioids and substance use disorder symptoms at age 35: a national longitudinal study. Pain. 2016;157(10):2173–8.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  11. McCabe SE, West BT, Teter CJ, Boyd CJ. Medical and nonmedical use of prescription opioids among high school seniors in the United States. Arch Pediatr Adolesc Med. 2012;166(9):797–802.

    Article  PubMed  PubMed Central  Google Scholar 

  12. • Miech R, Johnston L, O’Malley PM, Keyes KM, Heard K. Prescription opioids in adolescence and future opioid misuse. Pediatrics. 2015;136(5):e1169–77. Reports on risk factors associated with future opioid misuse among a national sample of youth prospectively followed from 12th grade through age 23 years.

  13. Miech RA, Johnston LD, O’Malley PM, Bachman JG, Schulenberg JE. Monitoring the future national survey results on drug use, 1975–2014: secondary school students. Ann Arbor: Institute for Social Research, The University of Michigan; 2015.

    Google Scholar 

  14. Ross-Durow PL, McCabe SE, Boyd CJ. Adolescents’ access to their own prescription medications in the home. J Adolesc Health. 2013;53(2):260–4.

    Article  PubMed  PubMed Central  Google Scholar 

  15. Edlund MJ, Forman-Hoffman VL, Winder CR, Heller DC, Kroutil LA, Lipari RN, et al. Opioid abuse and depression in adolescents: results from the National Survey on Drug Use and Health. Drug Alcohol Depend. 2015;152:131–8.

    Article  PubMed  Google Scholar 

  16. Boyd CJ, Young A, McCabe SE. Psychological and drug abuse symptoms associated with nonmedical use of opioid analgesics among adolescents. Subst Abus. 2014;35(3):284–9.

    Article  PubMed  PubMed Central  Google Scholar 

  17. Austin AE, Shanahan ME, Zvara BJ. Association of childhood abuse and prescription opioid use in early adulthood. Addict Behav. 2018;76:265–9.

    Article  PubMed  Google Scholar 

  18. Stein MD, Conti MT, Kenney S, Anderson BJ, Flori JN, Risi MM, et al. Adverse childhood experience effects on opioid use initiation, injection drug use, and overdose among persons with opioid use disorder. Drug Alcohol Depend. 2017;179:325–9.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Cicero TJ, Ellis MS, Surratt HL, Kurtz SP. The changing face of heroin use in the United States: a retrospective analysis of the past 50 years. JAMA Psychiatry. 2014;71(7):821–6.

    Article  PubMed  Google Scholar 

  20. Cerda M, Santaella J, Marshall BD, Kim JH, Martins SS. Nonmedical prescription opioid use in childhood and early adolescence predicts transitions to heroin use in young adulthood: a national study. J Pediatr. 2015;167(3):605–12 e1–2.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Palamar JJ, Shearston JA, Dawson EW, Mateu-Gelabert P, Ompad DC. Nonmedical opioid use and heroin use in a nationally representative sample of us high school seniors. Drug Alcohol Depend. 2016;158:132–8.

    Article  PubMed  Google Scholar 

  22. •• Cicero TJ, Ellis MS, Kasper ZA. Increased use of heroin as an initiating opioid of abuse. Addict Behav. 2017;74:63–6. Reports on recent trends in first opioid of misuse among adults entering substance use disorder treatment for an opioid use disorder.

  23. Rosenblum D, Unick GJ, Ciccarone D. The entry of Colombian-sourced heroin into the US market: the relationship between competition, price, and purity. Int J Drug Policy. 2014;25(1):88–95.

    Article  PubMed  Google Scholar 

  24. O’Donnell JK, Gladden RM, Seth P. Trends in deaths involving heroin and synthetic opioids excluding methadone, and law enforcement drug product reports, by census region—United States, 2006-2015. MMWR Morb Mortal Wkly Rep. 2017;66(34):897–903.

    Article  PubMed  PubMed Central  Google Scholar 

  25. Suzuki J, El-Haddad S. A review: fentanyl and non-pharmaceutical fentanyls. Drug Alcohol Depend. 2017;171:107–16.

    Article  PubMed  CAS  Google Scholar 

  26. Julie K. O’Donnell PRMG, PhD; Puja Seth, PhD. Trends in deaths involving heroin and synthetic opioids excluding methadone, and law enforcement drug product reports, by census region—United States, 2006–2015. Morb Mortal Wkly Rep 2017;66:897–903.

  27. • Hadland SE, Levy S. Objective testing: urine and other drug tests. Child Adolesc Psychiatr Clin N Am. 2016;25(3):549–65. Review covering toxicology testing in clinical practice including types of samples used for testing, indications for testing, and practical concerns associated with testing in adolescents.

    Article  PubMed  PubMed Central  Google Scholar 

  28. Viral Hepatitis Surveillance, United States 2015. Center for Disease Control; 2015.

  29. • Zibbell JE, Asher AK, Patel RC, Kupronis B, Iqbal K, Ward JW, et al. Increases in acute hepatitis C virus infection related to a growing opioid epidemic and associated injection drug use, United States, 2004 to 2014. Am J Public Health. 2018;108(2):175–81. Compares trends in opioid injection with the trends in the incidence of acute hepatitis C virus infection in the USA.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Thorpe LE, Ouellet LJ, Hershow R, Bailey SL, Williams IT, Williamson J, et al. Risk of hepatitis C virus infection among young adult injection drug users who share injection equipment. Am J Epidemiol. 2002;155(7):645–53.

    Article  PubMed  Google Scholar 

  31. Moyer VA. Force USPST. Screening for hepatitis C virus infection in adults: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2013;159(5):349–57.

    Article  PubMed  Google Scholar 

  32. Hakansson A, Schlyter F, Berglund M. Factors associated with history of non-fatal overdose among opioid users in the Swedish criminal justice system. Drug Alcohol Depend. 2008;94(1–3):48–55.

    Article  PubMed  CAS  Google Scholar 

  33. Kerr T, Fairbairn N, Tyndall M, Marsh D, Li K, Montaner J, et al. Predictors of non-fatal overdose among a cohort of polysubstance-using injection drug users. Drug Alcohol Depend. 2007;87(1):39–45.

    Article  PubMed  Google Scholar 

  34. Warner M, Chen LH, Makuc DM, Anderson RN, Minino AM. Drug poisoning deaths in the United States, 1980-2008. NCHS Data Brief. 2011;81:1–8.

    Google Scholar 

  35. Jones CM, McAninch JK. Emergency department visits and overdose deaths from combined use of opioids and benzodiazepines. Am J Prev Med. 2015;49(4):493–501.

    Article  PubMed  Google Scholar 

  36. Pabayo R, Alcantara C, Kawachi I, Wood E, Kerr T. The role of depression and social support in non-fatal drug overdose among a cohort of injection drug users in a Canadian setting. Drug Alcohol Depend. 2013;132(3):603–9.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Seal KH, Kral AH, Gee L, Moore LD, Bluthenthal RN, Lorvick J, et al. Predictors and prevention of nonfatal overdose among street-recruited injection heroin users in the San Francisco Bay Area, 1998-1999. Am J Public Health. 2001;91(11):1842–6.

    Article  PubMed  PubMed Central  CAS  Google Scholar 

  38. Coffin PO, Tracy M, Bucciarelli A, Ompad D, Vlahov D, Galea S. Identifying injection drug users at risk of nonfatal overdose. Acad Emerg Med Off J Soc Acad Emerg Med. 2007;14(7):616–23.

    Article  Google Scholar 

  39. Rossow I, Lauritzen G. Balancing on the edge of death: suicide attempts and life-threatening overdoses among drug addicts. Addiction. 1999;94(2):209–19.

    Article  PubMed  CAS  Google Scholar 

  40. Gossop M, Stewart D, Treacy S, Marsden J. A prospective study of mortality among drug misusers during a 4-year period after seeking treatment. Addiction. 2002;97(1):39–47.

    Article  PubMed  Google Scholar 

  41. Bartoli F, Carra G, Brambilla G, Carretta D, Crocamo C, Neufeind J, et al. Association between depression and non-fatal overdoses among drug users: a systematic review and meta-analysis. Drug Alcohol Depend. 2014;134:12–21.

    Article  PubMed  Google Scholar 

  42. Maloney E, Degenhardt L, Darke S, Nelson EC. Are non-fatal opioid overdoses misclassified suicide attempts? Comparing the associated correlates. Addict Behav. 2009;34(9):723–9.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Silva K, Schrager SM, Kecojevic A, Lankenau SE. Factors associated with history of non-fatal overdose among young nonmedical users of prescription drugs. Drug Alcohol Depend. 2013;128(1–2):104–10.

    Article  PubMed  Google Scholar 

  44. Yule AM, Carrellas, N. W., Fitzgerald, M., McKowen, J. W., Nargiso, J. E., Bergman, B. G., Kelly, J. F. Risk factors for overdose in treatment-seeking youth with substance use disorders during follow-up. The J Clin Psychiatry (in Press).

  45. Principles of adolescent substance use disorder treatment: a research-based guide. National Institute on Drug Abuse (NIDA); 2014.

  46. Winters KC, Tanner-Smith EE, Bresani E, Meyers K. Current advances in the treatment of adolescent drug use. Adolesc Health Med Ther. 2014;5:199–210.

    Article  PubMed  PubMed Central  Google Scholar 

  47. •• Committee On Substance USE, Prevention. Medication-assisted treatment of adolescents with opioid use disorders. Pediatrics. 2016;138(3). Reviews effective treatment for opioid use disorders in youth and advocates for improving access to medication treatment for opioid use disorders in adolescents and young adults.

  48. •• Chang DC, Klimas J, Wood E, Fairbairn N. Medication-assisted treatment for youth with opioid use disorder: current dilemmas and remaining questions. Am J Drug Alcohol Abuse. 2018;44(2):143–6. Commentary on dilemmas and questions regarding the use of medication for opioid use disorders in youth. Recommends buprenorphine/naloxone as first-line treatment.

    Article  PubMed  Google Scholar 

  49. Connery HS. Medication-assisted treatment of opioid use disorder: review of the evidence and future directions. Harv Rev Psychiatry. 2015;23(2):63–75.

    Article  PubMed  Google Scholar 

  50. Marsch LA, Bickel WK, Badger GJ, Stothart ME, Quesnel KJ, Stanger C, et al. Comparison of pharmacological treatments for opioid-dependent adolescents: a randomized controlled trial. Arch Gen Psychiatry. 2005;62(10):1157–64.

    Article  PubMed  CAS  Google Scholar 

  51. Woody GE, Poole SA, Subramaniam G, Dugosh K, Bogenschutz M, Abbott P, et al. Extended vs short-term buprenorphine-naloxone for treatment of opioid-addicted youth: a randomized trial. JAMA. 2008;300(17):2003–11.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Marsch LA, Moore SK, Borodovsky JT, Solhkhah R, Badger GJ, Semino S, et al. A randomized controlled trial of buprenorphine taper duration among opioid-dependent adolescents and young adults. Addiction. 2016;111(8):1406–15.

    Article  PubMed  PubMed Central  Google Scholar 

  53. Fishman MJ, Winstanley EL, Curran E, Garrett S, Subramaniam G. Treatment of opioid dependence in adolescents and young adults with extended release naltrexone: preliminary case-series and feasibility. Addiction. 2010;105(9):1669–76.

    Article  PubMed  Google Scholar 

  54. Vo HT, Burgower R, Rozenberg I, Fishman M. Home-based delivery of XR-NTX in youth with opioid addiction. J Subst Abus Treat. 2018;85:84–9.

    Article  Google Scholar 

  55. Hadland SE, Wharam JF, Schuster MA, Zhang F, Samet JH, Larochelle MR. Trends in receipt of buprenorphine and naltrexone for opioid use disorder among adolescents and young adults, 2001-2014. JAMA Pediatr. 2017;171(8):747–55.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Sordo L, Barrio G, Bravo MJ, Indave BI, Degenhardt L, Wiessing L, et al. Mortality risk during and after opioid substitution treatment: systematic review and meta-analysis of cohort studies. BMJ. 2017;357:j1550.

    Article  PubMed  PubMed Central  Google Scholar 

  57. Principles of drug addiction treatment: a research-based guide. National Institute on Drug Abuse, National Institutes of Health; 2018.

  58. • Godley MD, Passetti LL, Subramaniam GA, Funk RR, Smith JE, Meyers RJ. Adolescent Community Reinforcement Approach implementation and treatment outcomes for youth with opioid problem use. Drug Alcohol Depend. 2017;174:9–16. Reports on feasibility, acceptability, and efficacy of the Adolescent Community Reinforcement Approach for youth with primary problem opioid use compared to youth with primary marijuana or alcohol problem use.

    Article  PubMed  PubMed Central  Google Scholar 

  59. Godley SH, Meyers RJ, Smith JE, Karvinen T, Titus JC, Godley MD, et al. The adolescent community reinforcement approach for adolescent cannabis users, Cannabis Youth Treatment (CYT) Susbtance Abuse and Mental Health Services Administration (DHHS/PHS), Rockville, MD. Center for Substance Abuse Treatment. ; 2001.

  60. Roozen HG, de Waart R, van der Kroft P. Community reinforcement and family training: an effective option to engage treatment-resistant substance-abusing individuals in treatment. Addiction. 2010;105(10):1729–38.

    Article  PubMed  Google Scholar 

  61. Kirby KC, Versek B, Kerwin ME, Meyers K, Benishek LA, Bresani E, et al. Developing community reinforcement and family training (CRAFT) for parents of treatment-resistant adolescents. J Child Adolesc Subst Abuse. 2015;24(3):155–65.

    Article  PubMed  PubMed Central  Google Scholar 

  62. Spoth R, Trudeau L, Shin C, Ralston E, Redmond C, Greenberg M, et al. Longitudinal effects of universal preventive intervention on prescription drug misuse: three randomized controlled trials with late adolescents and young adults. Am J Public Health. 2013;103(4):665–72.

    Article  PubMed  PubMed Central  Google Scholar 

  63. Thompson EL, Rao PSS, Hayes C, Purtill C. Dispensing naloxone without a prescription: survey evaluation of Ohio pharmacists. J Pharm Pract. 2018;897190018759225

Download references

Author information

Authors and Affiliations

  1. Pediatric Psychopharmacology Program, Division of Child Psychiatry, Massachusetts General Hospital, Boston, MA, 02114, USA

    Amy M. Yule, Rachael M. Lyons & Timothy E. Wilens

  2. Addiction Recovery Management Service (ARMS), Center for Addiction Medicine, Massachusetts General Hospital, 151 Merrimac Street, 6th Floor, Boston, MA, 02114, USA

    Amy M. Yule & Timothy E. Wilens

  3. Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, MA, 02114, USA

    Amy M. Yule & Timothy E. Wilens

Authors
  1. Amy M. Yule
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rachael M. Lyons
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Timothy E. Wilens
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Amy M. Yule.

Ethics declarations

Conflict of Interest

Amy M. Yule received grant support from the Massachusetts General Hospital Louis V. Gerstner III Research Scholar Award from 2014 to 2016. Dr. Yule is currently receiving funding through the AACAP Physician Scientist Program in Substance Abuse 5K12DA000357-17. She was a consultant to Phoenix House from 2015 to 2017 and is currently a consultant to the Gavin Foundation (clinical services).

Timothy E. Wilens receives or has received grant support from the following sources: NIH(NIDA). Dr. Timothy Wilens is or has been a consultant for the following: Alcobra, Neurovance/Otsuka, and Ironshore. Dr. Timothy Wilens has a published book Straight Talk About Psychiatric Medications for Kids (Guilford Press) and co/edited books ADHD in Adults and Children (Cambridge University Press), the Massachusetts General Hospital Comprehensive Clinical Psychiatry (Elsevier), and Massachusetts General Hospital Psychopharmacology and Neurotherapeutics (Elsevier). Dr. Wilens is co/owner of a copyrighted diagnostic questionnaire (Before School Functioning Questionnaire), and he has a licensing agreement with Iron shore (BSFQ Questionnaire). Dr. Wilens is Chief, Division of Child and Adolescent Psychiatry and (Co) Director of the Center for Addiction Medicine at Massachusetts General Hospital. He serves as a consultant to the US National Football League (ERM Associates), U.S. Minor/Major League Baseball, Bay Cove Human Services (Clinical Services), Phoenix/Gavin House and Bay Cove Human Services.

Rachael M. Lyons declares no potential conflicts of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Adolescent Medicine

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yule, A.M., Lyons, R.M. & Wilens, T.E. Opioid Use Disorders in Adolescents—Updates in Assessment and Management. Curr Pediatr Rep 6, 99–106 (2018). https://doi.org/10.1007/s40124-018-0161-z

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40124-018-0161-z

Keywords

Search

Navigation